Eli Lilly (LLY)
954.52
+34.75 (3.78%)
NYSE · Last Trade: Apr 1st, 4:53 PM EDT
Detailed Quote
| Previous Close | 919.77 |
|---|---|
| Open | 926.88 |
| Bid | 955.77 |
| Ask | 956.00 |
| Day's Range | 925.99 - 976.68 |
| 52 Week Range | 623.78 - 1,133.95 |
| Volume | 6,166,404 |
| Market Cap | 913.08B |
| PE Ratio (TTM) | 41.59 |
| EPS (TTM) | 22.9 |
| Dividend & Yield | 6.920 (0.72%) |
| 1 Month Average Volume | 2,823,726 |
Chart
About Eli Lilly (LLY)
Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
News & Press Releases
The pharmaceutical giant still has plenty of work to do to recover from recent woes.
Via The Motley Fool · April 1, 2026
What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 4.7% in the afternoon session after the FDA approved Foundayo (orforglipro...
Via StockStory · April 1, 2026
Eli Lilly shares surged after FDA approval of its oral obesity drug Foundayo, boosting growth prospects in the weight-loss market.
Via Benzinga · April 1, 2026
Eli Lilly stock jumped midday Wednesday after the FDA approved its weight-loss pill, now called Foundayo.
Via Investor's Business Daily · April 1, 2026

Eli Lilly (LLY) shares rallied after finding support at a formed resistance level. They may hit resistance at a former support level.
Via Benzinga · April 1, 2026
Eli Lilly & Co (NYSE:LLY): A Prime Dividend Growth Candidate Backed by Strong Profitabilitychartmill.com
Via Chartmill · March 30, 2026
This pharmaceutical giant appears well positioned for a potential stock split in 2026.
Via The Motley Fool · April 1, 2026

Centessa Pharma to be acquired by Eli Lilly for $8B. Analyst downgrades rating. Deal includes $6.3B in cash and potential $1.5B in milestones.
Via Benzinga · April 1, 2026
Hasbro is expected to announce its first-quarter results soon, and analysts are projecting a single-digit decline in its EPS.
Via Barchart.com · April 1, 2026
Nasdaq will release its first-quarter earnings soon, and analysts anticipate a double-digit bottom-line growth.
Via Barchart.com · April 1, 2026
Willis Towers Watson will release its first-quarter earnings soon, and analysts anticipate a double-digit bottom-line growth.
Via Barchart.com · April 1, 2026
Wall Street Ends a Rough Quarter With Its Best Day, Iran Hope Ignites the Rallychartmill.com
Via Chartmill · April 1, 2026
A pharma giant wants to buy the innovative drug developer.
Via The Motley Fool · March 31, 2026
This little-known biotech company has a different strategy than the established weight-loss drug market leaders. But is it likely to be successful?
Via The Motley Fool · March 31, 2026
Eli Lilly to acquire Centessa Pharmaceuticals for $6.3B. CNTA stock surges 45% as Lilly expands its neuroscience and sleep medicine pipeline.
Via Benzinga · March 31, 2026
Today, March 31, 2026, the biotechnology landscape has been fundamentally reshaped. Eli Lilly and Company (NYSE: LLY) has officially announced a definitive agreement to acquire Centessa Pharmaceuticals (Nasdaq: CNTA) in a blockbuster transaction valued at up to $7.8 billion. This acquisition marks a watershed moment for the treatment of sleep-wake disorders and underscores the intense [...]
Via Finterra · March 31, 2026
Date: March 31, 2026 Introduction In the spring of 2026, the global pharmaceutical landscape is increasingly defined by the gravitational pull of a single entity: Eli Lilly and Company (NYSE: LLY). Once a steady mid-tier giant known for insulin and antidepressants, Lilly has transformed into the world’s first trillion-dollar healthcare titan. Today’s announcement—a definitive $6.3 [...]
Via Finterra · March 31, 2026
Eli Lilly has expanded its partnership with Insilico Medicine to bring AI developed medicine into global market.
Via Barchart.com · March 31, 2026
The takeover fills a glaring hole in Eli Lilly's pipeline, says one analyst.
Via Investor's Business Daily · March 31, 2026
There are some tempting bargains if you know where to look.
Via The Motley Fool · March 31, 2026
Via MarketBeat · March 31, 2026

Inflation and growth worries impacted tech stocks as investors question AI price tags today, March 30, 2026.
Via The Motley Fool · March 30, 2026
The healthcare stock may not be running out of growth catalysts anytime soon.
Via The Motley Fool · March 30, 2026
You can sleep peacefully at night owning these Vanguard ETFs.
Via The Motley Fool · March 30, 2026
Pfizer is behind Eli Lilly and Novo Nordisk in the GLP-1 race, but long-term investors shouldn't count the company out.
Via The Motley Fool · March 29, 2026
